Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Biosimilars: approval and acceptance?

DeMartino JK.

J Natl Compr Canc Netw. 2011 Feb;9 Suppl 3:S6-9. No abstract available.

PMID:
21357668
2.

Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticals.

Blackstone EA, Fuhr JP Jr.

Future Med Chem. 2010 Nov;2(11):1641-9. doi: 10.4155/fmc.10.248.

PMID:
21428836
3.

[The industry recommends increased use. Biosimilars are like generics, but still not].

Bergström R, Nyblom K.

Lakartidningen. 2010 Oct 20-26;107(42):2584-5. Swedish. No abstract available.

PMID:
21137555
5.

Congress works to permit 'biosimilar' drugs very soon.

Carroll J.

Manag Care. 2009 Apr;18(4):7-8. No abstract available.

6.

Implementation of the biosimilar pathway: economic and policy issues.

Grabowski H, Long G, Mortimer R.

Seton Hall Law Rev. 2011;41(2):511-57. No abstract available.

PMID:
21739758
7.

[Biosimilars attack...].

Breimer L.

Lakartidningen. 2010 Nov 10-16;107(45):2828. Swedish. No abstract available.

PMID:
21179871
8.

NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.

Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, Goldberg SE, Gottlieb S, Johnson PE, Lyman GH, Markus R, Matulonis UA, Reinke D, Li EC, DeMartino J, Larsen JK, Hoffman JM.

J Natl Compr Canc Netw. 2011 Sep;9 Suppl 4:S1-22.

PMID:
21976013
9.

Blockbusters for cheap? The difficulties surrounding generic biologics.

Josephson SA, Johnston SC, Hauser SL.

Ann Neurol. 2013 Sep;74(3):A7-8. doi: 10.1002/ana.24023. No abstract available.

PMID:
24115256
10.

Biosimilars: it's not as simple as cost alone.

Roger SD, Goldsmith D.

J Clin Pharm Ther. 2008 Oct;33(5):459-64. doi: 10.1111/j.1365-2710.2008.00942.x.

PMID:
18834359
11.

'Biosimilar' drugs poised to penetrate market.

Ledford H.

Nature. 2010 Nov 4;468(7320):18-9. doi: 10.1038/468018a. No abstract available.

PMID:
21048737
12.

[Biosimilars and medico-economic aspects].

Borget I, Grivel T.

Bull Cancer. 2010 May;97(5):589-95. doi: 10.1684/bdc.2010.1093. French.

13.

[Biosimilar products--cheaper version of biological drugs. New possibilities within several therapeutic fields].

Mellstedt H.

Lakartidningen. 2009 Jun 3-9;106(23):1563-6. Review. Swedish. No abstract available.

PMID:
19583014
14.

Basic facts about biosimilars.

Nowicki M.

Kidney Blood Press Res. 2007;30(5):267-72. Epub 2007 Jul 4. Review.

15.

SuperGenerics: a better alternative for biogenerics.

Charles SA.

Drug Discov Today. 2005 Apr 15;10(8):533-5. No abstract available.

PMID:
15837591
16.

US biosimilar pathway unlikely to be used: developers will opt for a traditional BLA filing.

Wiatr C.

BioDrugs. 2011 Feb 1;25(1):63-7. doi: 10.2165/11588410-000000000-00000. Review.

PMID:
21222498
17.

[Generics in psychiatry--do they have the same therapeutic equivalence as the original?].

Kasper S, Lentner S.

Neuropsychiatr. 2008;22(4):221-2. German. No abstract available.

PMID:
19080992
18.

Biotechs go generic: the same but different.

Ledford H.

Nature. 2007 Sep 20;449(7160):274-6. No abstract available.

PMID:
17882194
19.

Biosimilars: how similar or dissimilar are they?

Roger SD.

Nephrology (Carlton). 2006 Aug;11(4):341-6. Review.

PMID:
16889575
20.

Supplemental Content

Support Center